- Home
- HAYW vs ZLAB Comparison
HAYW vs ZLAB Comparison
Compare HAYW & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAYW
- ZLAB
- Stock Information
- Founded
- HAYW 1925
- ZLAB 2013
- Country
- HAYW United States
- ZLAB China
- Employees
- HAYW N/A
- ZLAB N/A
- Industry
- HAYW Electronic Components
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- HAYW Technology
- ZLAB Health Care
- Exchange
- HAYW Nasdaq
- ZLAB Nasdaq
- Market Cap
- HAYW 3.5B
- ZLAB 3.4B
- IPO Year
- HAYW 2021
- ZLAB 2017
- Fundamental
- Price
- HAYW $15.12
- ZLAB $32.58
- Analyst Decision
- HAYW Hold
- ZLAB Buy
- Analyst Count
- HAYW 5
- ZLAB 6
- Target Price
- HAYW $17.33
- ZLAB $57.22
- AVG Volume (30 Days)
- HAYW 2.0M
- ZLAB 819.9K
- Earning Date
- HAYW 10-28-2025
- ZLAB 11-11-2025
- Dividend Yield
- HAYW N/A
- ZLAB N/A
- EPS Growth
- HAYW 46.31
- ZLAB N/A
- EPS
- HAYW 0.60
- ZLAB N/A
- Revenue
- HAYW $1,083,088,000.00
- ZLAB $427,799,000.00
- Revenue This Year
- HAYW $5.74
- ZLAB $42.62
- Revenue Next Year
- HAYW $5.40
- ZLAB $55.12
- P/E Ratio
- HAYW $25.26
- ZLAB N/A
- Revenue Growth
- HAYW 8.77
- ZLAB 32.56
- 52 Week Low
- HAYW $11.10
- ZLAB $20.17
- 52 Week High
- HAYW $16.87
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- HAYW 40.77
- ZLAB 48.51
- Support Level
- HAYW $15.56
- ZLAB $31.68
- Resistance Level
- HAYW $16.11
- ZLAB $33.06
- Average True Range (ATR)
- HAYW 0.39
- ZLAB 1.34
- MACD
- HAYW -0.13
- ZLAB 0.21
- Stochastic Oscillator
- HAYW 3.72
- ZLAB 80.97
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.